Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR to fix bad blood: a new tool in basic and clinical hematology

28 Mar 2019

Abstract excerpt

Advances in genome engineering in the last decade, particularly in the development of programmable nucleases, have made it possible to edit the genomes of most cell types precisely and efficiently. Chief among these advances, the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is a novel, versatile and easy-to-use tool to edit genomes irrespective of their complexity, with multiple...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Cytomegalovirus and herpesvirus research
Share to Mosquito-borne diseases and control

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30923099
DOI: 10.3324/haematol.2018.211359

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR to fix bad blood: a new tool in basic and clinical hematologyPMID 30923099Read ↗

Therapeutic gene editing in haematological disorders with CRISPR /Cas9Semantic proximity Read ↗

CRISPR/Cas9-mediated gene editing. A promising strategy in hematological disorders.Semantic proximity Read ↗

The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies.Semantic proximity Read ↗

CRISPR RNA-Guided Gene Editing and its Clinical Research Applications in Hematology with Focus on Inherited Germline Predisposition to Hematologic MalignanciesSemantic proximity Read ↗

The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translationSemantic proximity Read ↗

CRISPR ‐Cas9 technology and its application in haematological disordersSemantic proximity Read ↗

CRISPR medicine for blood disorders: Progress and challenges in deliverySemantic proximity Read ↗

High-Throughput CRISPR Screening in Hematological NeoplasmsSemantic proximity Read ↗

Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo ProspectsSemantic proximity Read ↗

CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedsideSemantic proximity Read ↗

Treating genetic blood disorders in the era of CRISPR-mediated genome editing.Semantic proximity Read ↗

Therapy Development by Genome Editing of Hematopoietic Stem CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.